# GALNT4

## Overview
GALNT4, or polypeptide N-acetylgalactosaminyltransferase 4, is a gene that encodes a type II transmembrane protein involved in the initiation of mucin-type O-glycosylation. This enzyme belongs to the GalNAc-T family and is responsible for transferring N-acetylgalactosamine to serine or threonine residues on proteins, a critical step in the synthesis of glycoproteins that play roles in protein stability, signaling, and cell-cell interactions (Guo2024GALNT4; Chia2016Short). The GALNT4 protein is characterized by a catalytic domain that determines substrate selectivity and a lectin domain that aids in glycosylation (Garay2022Polypeptide). It is predominantly localized in the Golgi apparatus and is expressed in various human tissues, suggesting its involvement in diverse biological pathways (Kato2021Polypeptide). GALNT4's interactions with other proteins, such as ASK1, and its role in signaling pathways like NF-κB, underscore its importance in cellular processes, including apoptosis and inflammation (Zhang2021Role; Guo2024GALNT4). The gene's altered expression has been linked to several clinical conditions, including cardiovascular diseases and cancer, highlighting its potential significance in health and disease (Sheta2017Altered).

## Structure
The GALNT4 protein, or polypeptide N-acetylgalactosaminyltransferase 4, is a member of the GalNAc-T family, which initiates mucin-type O-glycosylation by transferring N-acetylgalactosamine to serine or threonine residues on proteins. Structurally, GALNT4 is a type II transmembrane protein characterized by a short N-terminal cytoplasmic tail and a C-terminal domain that includes a stem region and a globular catalytic domain (Chia2016Short). The catalytic domain is responsible for substrate selectivity and is poorly conserved between isoforms but highly conserved among orthologous isoforms across species (Chia2016Short). 

GALNT4 also contains a lectin domain, which assists in the glycosylation process by facilitating the addition of GalNAc on existing substrates (Garay2022Polypeptide). The protein's structure has been studied using X-ray crystallography, and its conformation is available in the Protein Data Bank under the identifier 5NQA (Garay2022Polypeptide). Post-translational modifications of GALNT4 may include glycosylation and phosphorylation, contributing to its functional diversity. Splice variants of GALNT4 can result in different isoforms, potentially leading to variations in its enzymatic activity and substrate specificity (Garay2022Polypeptide).

## Function
GALNT4 (polypeptide N-acetylgalactosaminyltransferase 4) is an enzyme that plays a crucial role in the process of O-linked glycosylation, where it initiates the attachment of N-acetylgalactosamine (GalNAc) to serine or threonine residues on proteins. This modification is essential for the synthesis of mucin-type glycoproteins, which are important for protein stability, signaling, and cell-cell interactions (Guo2024GALNT4; Chia2016Short). GALNT4 is localized in the Golgi apparatus, where it contributes to the regulation of O-glycan patterns by transferring GalNAc to both glycosylated and unglycosylated peptides (Chia2016Short).

In healthy human cells, GALNT4 is expressed in various tissues, including the liver, small intestine, stomach, pancreas, thyroid, spleen, lymph node, and bone marrow (Kato2021Polypeptide). Its expression patterns suggest a role in diverse biological pathways, although its precise functions in normal physiology are not fully understood. GALNT4 is also involved in endothelial-platelet interactions by glycosylating the P-selectin glycoprotein ligand (PSGL-1) in monocytes, which is crucial for the inflammatory response and cardiovascular health (Guo2024GALNT4). Despite its involvement in these processes, the specific role of GALNT4 in healthy human cells requires further investigation (Chia2016Short).

## Clinical Significance
GALNT4 has been associated with various clinical conditions, primarily through its altered expression or genetic variations. A specific variant, GalNAc-T4 V506I (p.[Val506Ile]), has been linked to a reduced risk of acute coronary syndrome (ACS), although this association was not significant in haplotypic tests (Kato2021Polypeptide). In cancer research, GALNT4 has shown varying roles. It has been implicated in breast carcinogenesis, where low expression is associated with poor progression-free survival and overall survival in clear cell renal cell carcinoma patients (Sheta2017Altered). However, in high-grade serous ovarian cancer (HGSC), GALNT4 showed very weak or no expression in both epithelial ovarian cancer (EOC) cell lines and tumor samples, suggesting it may not play a significant role in these cancer types (Sheta2017Altered). Despite its limited expression in HGSC, the altered expression of GALNT4 in other cancers suggests its potential involvement in cancer progression and prognosis. The diverse roles of GALNT4 in different tissues and conditions highlight the complexity of its function and the need for further research to fully understand its clinical significance (Chia2016Short).

## Interactions
GALNT4, or polypeptide N-acetylgalactosaminyltransferase 4, is known to participate in several protein interactions that influence its function in cellular processes. One significant interaction is with the apoptosis signal-regulating kinase 1 (ASK1) protein. GALNT4 directly binds to ASK1, inhibiting its oligomerization, which is essential for ASK1's phosphorylation and activation. This interaction plays a crucial role in regulating apoptosis and cardiac hypertrophy, as demonstrated by coimmunoprecipitation and GST pulldown assays in 293T cells and neonatal rat cardiomyocytes (NRCMs) (Zhang2021Role).

In addition to its role in cardiac cells, GALNT4 is involved in the inflammatory response in human umbilical vein endothelial cells (HUVECs) via the NF-κB signaling pathway. GALNT4 overexpression enhances NF-κB activity, leading to increased degradation of IκBα and translocation of the p65 NF-κB subunit to the nucleus. This activation promotes the expression of cell adhesion molecules, facilitating monocyte adhesion and migration (Guo2024GALNT4). These interactions highlight GALNT4's role in modulating key signaling pathways through its binding activities.


## References


[1. (Zhang2021Role) Bin-Bin Zhang, Lu Gao, Qin Yang, Yuan Liu, Xiao-Yue Yu, Ji-Hong Shen, Wen-Cai Zhang, Zhan-Ying Han, Shao-Ze Chen, and Sen Guo. Role of galnt4 in protecting against cardiac hypertrophy through ask1 signaling pathway. Cell Death &amp; Disease, October 2021. URL: http://dx.doi.org/10.1038/s41419-021-04222-5, doi:10.1038/s41419-021-04222-5. This article has 4 citations.](https://doi.org/10.1038/s41419-021-04222-5)

[2. (Sheta2017Altered) Razan Sheta, Magdalena Bachvarova, Marie Plante, Jean Gregoire, Marie-Claude Renaud, Alexandra Sebastianelli, Ion Popa, and Dimcho Bachvarov. Altered expression of different galnac-transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. International Journal of Oncology, 51(6):1887–1897, October 2017. URL: http://dx.doi.org/10.3892/ijo.2017.4147, doi:10.3892/ijo.2017.4147. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2017.4147)

[3. (Chia2016Short) Joanne Chia, Germaine Goh, and Frederic Bard. Short o-galnac glycans: regulation and role in tumor development and clinical perspectives. Biochimica et Biophysica Acta (BBA) - General Subjects, 1860(8):1623–1639, August 2016. URL: http://dx.doi.org/10.1016/j.bbagen.2016.03.008, doi:10.1016/j.bbagen.2016.03.008. This article has 103 citations.](https://doi.org/10.1016/j.bbagen.2016.03.008)

[4. (Garay2022Polypeptide) Yohana Camila Garay, Romina Beatriz Cejas, Virginia Lorenz, Natacha Zlocowski, Pedro Parodi, Franco Alejandro Ferrero, Genaro Angeloni, Valentina Alfonso García, Victor German Sendra, Ricardo Dante Lardone, and Fernando José Irazoqui. Polypeptide n-acetylgalactosamine transferase 3: a post-translational writer on human health. Journal of Molecular Medicine, 100(10):1387–1403, September 2022. URL: http://dx.doi.org/10.1007/s00109-022-02249-5, doi:10.1007/s00109-022-02249-5. This article has 0 citations.](https://doi.org/10.1007/s00109-022-02249-5)

[5. (Kato2021Polypeptide) Kentaro Kato, Lars Hansen, and Henrik Clausen. Polypeptide n-acetylgalactosaminyltransferase-associated phenotypes in mammals. Molecules, 26(18):5504, September 2021. URL: http://dx.doi.org/10.3390/molecules26185504, doi:10.3390/molecules26185504. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules26185504)

6. (Guo2024GALNT4) GALNT4 promotes the endothelial cell inflammatory response via the NF-κB signaling pathway. This article has 0 citations.